Tinzaparin Reduces the Risk of Recurrent Thromboembolic Events in Patients With Cancer

Article Information

DOI 
http://dx.doi.org/10.1177/1559897714568645
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 SAGE Publications

Author Information

  1. Lynne Lederman
  1. Agnes Y. Y. Lee, MD, MSc
    1. University of British Columbia, Vancouver, British Columbia, Canada
View Full Text

Article usage

AbstractFullPDF
Apr 2015500
May 2015200
Jun 2015900
Aug 20152211
Sep 20157500
Oct 2015532
Nov 20157921
Total19764

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Tinzaparin Reduces the Risk of Recurrent Thromboembolic Events in Patients With Cancer
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

recurrent venous thromboembolism
oncology
prevention
tinzaparin
warfarin
Long-Term Tinzaparin Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
NCT01130025